The role of microglia in prion diseases and possible therapeutic targets: a literature review

References

• Korth C, Peters P. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol. 2006;63(4):497.
   PubMedGoogle Scholar
• Marin L, Felício A, Bichuetti D, et al. Clinical findings in Creutzfeldt-Jakob disease mimicking dementia with Lewy bodies. Arq Neuropsiquiatr. 2008;66(3b):741–743.
   PubMed Web of Science ®Google Scholar
• Baker C, Lu Z, Zaitsev I, et al. Microglial activation varies in different models of Creutzfeldt-Jakob disease. J Virol. 1999;73(6):5089–5097.
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Prinz M. Origin of microglia: current concepts and past controversies. Cold Spring Harb Perspect Biol. 2015;7(8):a020537.
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Zhu C. Microglia in prion diseases. J Clin Investig. 2017;127(9):3230–3239.
   PubMed Web of Science ®Google Scholar
• Cherry JD, Olschowka JA, and O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11(1):98
   PubMed Web of Science ®Google Scholar
• Fumagalli M, Lombardi M, Gressens P, et al. How to reprogram microglia toward beneficial functions. Glia. 2018;66(12):2531–2549. (8).
   PubMed Web of Science ®Google Scholar
• Villemeur TB. Creutzfeldt–Jakob disease. Pediatric Neurology Part II. 2013;112:1191–1193.
   Google Scholar
• Vacca V. CJD. Nursing. 2016;46(3):36–42.
   PubMedGoogle Scholar
• Brandel J, and Knight R. Variant Creutzfeldt–Jakob disease. Human Prion Diseases. 2018;153:191–205.
   Google Scholar
• Iwasaki Y. Creutzfeldt-Jakob disease. Neuropathology. 2016;37(2):174–188.
   PubMed Web of Science ®Google Scholar
• Sitammagari KK, and Masood W. Creutzfeldt Jakob Disease. In: StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing;2021. Mar6 2021 Jan–. PMID: 29939637.
   Google Scholar
• Parchi P, Strammiello R, Giese A, et al. Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol. 2010;121(1):91–112.
   PubMed Web of Science ®Google Scholar
• Mackenzie G, Will R. Creutzfeldt-Jakob disease: recent developments. F1000 Research. 2017;6:2053.
   PubMedGoogle Scholar
• Heidenhain A. Klinische und anatomische Untersuchungen u¨ber eine eigenartige organische Erkrankung des Zentralnervensystems im Praesenium. Z Ges Neurol Psychiatr. 1929;118(1):49–114
   Google Scholar
• Meyer A, Leigh D, Bagg CE. A rare presenile dementia associated with cortical blindness (Heidenhain’s syndrome). J Neurol Neurosurg Psychiatry. 1954;17(2):129–133.
   PubMed Web of Science ®Google Scholar
• Mendonça L, Saffi P, Martini L, et al. Heidenhain variant of Creutzfeldt-Jakob disease in Brazil: a case report. Geriatrics, Gerontology and Aging. 2020;14(1):71–75
   Google Scholar
• Michel B, Meyerett-Reid C, Johnson T, et al. Incunabular immunological events in prion trafficking. Sci Rep. 2012;2(1). DOI:https://doi.org/10.1038/srep00440.
   Google Scholar
• Klein M, Kaeser P, Schwarz P, et al. Complement facilitates early prion pathogenesis. Nat Med. 2001;7(4):488–492.
   PubMed Web of Science ®Google Scholar
• Kouser L, Madhukaran S, Shastri A, et al. Emerging and novel functions of complement protein C1q. Front Immunol. 2015;6. DOI:https://doi.org/10.3389/fimmu.2015.00317.
   Google Scholar
• Kujala P, Raymond CR, Romejin M, et al. Prion uptake in the gut: identification of the first uptake and replication sites. Plos Pathog. 2011;7(12):e1002449. December.
   PubMed Web of Science ®Google Scholar
• Kraehenbuhl JP, Neutra MR. Epithelial M cells: differentiation and function. Annu Rev Cell Dev Biol. 2000;16(1):301–332.
   PubMedGoogle Scholar
• Heppner FL, Christ AD, Klein MA, et al. Transepithelial prion transport by M cells. Nat Med. 2001;7(9):976–977.
   PubMed Web of Science ®Google Scholar
• Veerhuis R, Boshuizen R, Morbin M, et al. Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q. Neurobiol Dis. 2005;19(1–2):273–282.
   PubMed Web of Science ®Google Scholar
• Voet S, Srinivasan S, Lamkanfi M, et al. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med. 2019;11(6). DOI:https://doi.org/10.15252/emmm.201810248
   PubMed Web of Science ®Google Scholar
• Van Everbroeck B, Dewulf E, Pals P, et al. The role of cytokines, astrocytes, microglia, and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging. 2002;23(1):59–64. (3).
   PubMed Web of Science ®Google Scholar
• Sharief M, Green A, Dick J, et al. Heightened intrathecal release of proinflammatory cytokines in Creutzfeldt-Jakob disease. Neurology. 1999;52(6):1289.
   PubMed Web of Science ®Google Scholar
• Williams A, Van Dam A, Ritchie D, et al. Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations. Brain Res. 1997;754(1–2):171–180.
   PubMed Web of Science ®Google Scholar
• Tribouillard-Tanvier D, Race B, Striebel J, et al. Early cytokine elevation, PrPres deposition, and gliosis in mouse scrapie: no effect on disease by deletion of cytokine genes IL-12p40 and IL-12p35. J Virol. 2012;86(19):10377–10383.
   PubMed Web of Science ®Google Scholar
• Xie W, Shi Q, Zhang J, et al. Abnormal activation of microglia accompanied with disrupted CX3CR1/CX3CL1 pathway in the brains of the hamsters infected with scrapie agent 263K. J Mol Neurosci. 2013;51(3):919–932.
   PubMed Web of Science ®Google Scholar
• Nuvolone M, Sorce S, Schwarz P, et al. Prion pathogenesis in the absence of NLRP3/ASC inflammasomes. PLOS ONE. 2015;10(2):e0117208.
   PubMed Web of Science ®Google Scholar
• Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging (Albany NY). 2012;4(3):166–175.
   PubMedGoogle Scholar
• Jo E, Shin D, Choi A. Autophagy: cellular defense to excessive inflammation. Microbes Infect. 2012;14(2):119–125.
   PubMed Web of Science ®Google Scholar
• Harris J, Hartman M, Roche C, et al. Autophagy controls IL-1β secretion by targeting Pro-IL-1β for degradation. J Biol Chem. 2011;286(11):9587–9597.
   PubMed Web of Science ®Google Scholar
• Lai M, Yao H, Shah S, et al. The NLRP3-caspase 1 inflammasome negatively regulates autophagy via TLR4-TRIF in prion peptide-infected microglia. Front Aging Neurosci. 2018;10. doi: https://doi.org/10.3389/fnagi.2018.00116.
   Google Scholar
• Rubinsztein D, DiFiglia M, Heintz N, et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy. 2005;1(1):11–22.
   PubMed Web of Science ®Google Scholar
• Li Q, Barres B. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol. 2017;18(4):225–242.
   PubMed Web of Science ®Google Scholar
• Conde JR, Streit WJ. Effect of aging on the microglial response to peripheral nerve injury. Neurobiol Aging. 2006;27(10):1451–1461.
   PubMed Web of Science ®Google Scholar
• Luo X, Chen S. The changing phenotype of microglia from homeostasis to disease. Translational Neurodegeneration [Internet]. 2012 [cited 29 August 2020];1(1):1–9.
   PubMedGoogle Scholar
• Gogoleva V, Drutskaya M, Atretkhany K. The role of microglia in the homeostasis of the central nervous system and neuroinflammation. Mol Biol. 2019;53(5):696–703.
   Web of Science ®Google Scholar
• García-Revilla A-B, Burguillos H, Espinosa-Oliva R, et al. Reformulating pro-oxidant microglia in neurodegeneration. J Clin Med. 2019;8(10):1719. Internet] ;():. Available from
   Web of Science ®Google Scholar
• Fourgeaud L, Través PG, Tufail Y, et al. TAM receptors regulate multiple features of microglial physiology. Nature. 2016;532(7598):240–244. Chiu, I. M. et al. A neurodegeneration-specific gene- expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385–401 (2013).; Yin, Z. et al. Immune hyperreactivity of Abeta plaque- associated microglia in Alzheimer’s disease. Neurobiol. Aging 55, 115–122 (2017).
   PubMed Web of Science ®Google Scholar
• Wolf S, Boddeke H, Kettenmann H. Microglia in physiology and disease. Annu Rev Physiol. 2017;79(1):619–643.
   PubMedGoogle Scholar
• Slattery C, Beck J, Harper L, et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer’s disease but not of prion or frontotemporal dementia. Alzheimers Dement. 2014;10(6):602–608.e4.
   PubMed Web of Science ®Google Scholar
• Mazaheri F, Snaidero N, Kleinberger G, et al. TREM 2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18(7):1186–1198.
   PubMed Web of Science ®Google Scholar
• Ayer A, Wojta K, Ramos E, et al. Frequency of the TREM2 R47H variant in various neurodegenerative disorders. Alzheimer Disease & Associated Disorders. 2019;33(4):327–330.
   PubMed Web of Science ®Google Scholar
• Zhu C, Herrmann U, Li B, et al. Triggering receptor expressed on myeloid cells-2 is involved in prion-induced microglial activation but does not contribute to prion pathogenesis in mouse brains. Neurobiol Aging. 2015;36(5):1994–2003.
   PubMed Web of Science ®Google Scholar
• Sanchez-Juan P, Bishop M, Kovacs G, et al. A genome wide association study links glutamate receptor pathway to sporadic Creutzfeldt-Jakob disease risk. PLOS ONE. 2015;10(4):e0123654.
   PubMed Web of Science ®Google Scholar
• Alperovitch A, Zerr I, Pocchiari M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet. 1999;353(9165):1673–1674.
   PubMed Web of Science ®Google Scholar
• Llorens F, López-González I, Thüne K, et al. Subtype and regional-specific neuroinflammation in sporadic Creutzfeld-Jakob disease. Front Aging Neurosci. 2014;6. doi: https://doi.org/10.3389/fnagi.2014.00198.
   Google Scholar
• Brandner S, Isenmann S, Raeber A, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 1996Jan25;379(6563):339–343. PMID: 8552188.
   PubMed Web of Science ®Google Scholar
• Szpac GM, Lewandowska, E, and Lechowicz, W. et al, The brain immune response in human prion diseases. Microglial activation and microglial disease. I. Sporadic Creutzfeldt-Jakob disease. The open drug discovery journal. 2006;44(3): 203-13(2).
   Google Scholar
• Obst J, Simon E, Mancuso R, et al. The role of microglia in prion diseases: a paradigm of functional diversity. Front Aging Neurosci. 2017;9(5). doi: https://doi.org/10.3389/fnagi.2017.00207
   Google Scholar
• Gomez-Nicola D, Fransen NL, Suzzi S, et al. Regulation of microglial proliferation during chronic neurodegeneration. J Neurosci. 2013;33(6):2481–2493.
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Moresco R, Presotto L, et al. An in vivo 11C-(R)-PK11195 PET and in vitro pathology study of microglia activation in Creutzfeldt-Jakob disease. Mol Neurobiol. 2017;55(4):2856–2868.
   PubMed Web of Science ®Google Scholar
• Carroll J, Chesebro B. Neuroinflammation, microglia, and cell-association during prion disease. Viruses. 2019;11(1):65. (7).
   PubMed Web of Science ®Google Scholar
• Calovi S, Mut-Arbona P, Sperlágh B. Microglia and the purinergic signaling system. Neuroscience. 2019;405:137–147.
   PubMed Web of Science ®Google Scholar
• Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8(6):752–758.
   PubMed Web of Science ®Google Scholar
• Fekete R, Cserép C, Lénárt N, et al. Microglia control the spread of neurotropic virus infection via P2Y12 signalling and recruit monocytes through P2Y12-independent mechanisms. Acta Neuropathol. 2018;136(3):461–482.
   PubMed Web of Science ®Google Scholar
• Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6(1). doi: https://doi.org/10.1186/1471-2377-6-12.
   Google Scholar
• McLarnon J, Ryu J, Walker D, et al. Upregulated expression of purinergic P2X7Receptor in Alzheimer disease and amyloid-β peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol. 2006;65(11):1090–1097.
   PubMed Web of Science ®Google Scholar
• Takenouchi T, Iwamaru Y, Imamura M, et al. Prion infection correlates with hypersensitivity of P2X7 nucleotide receptor in a mouse microglial cell line. FEBS Lett. 2007;581(16):3019–3026.
   PubMed Web of Science ®Google Scholar
• Spagnolli G, Rigoli M, Orioli S, et al. Full atomistic model of prion structure and conversion. PLoS Pathog. 2019Jul11;15(7):e1007864. PMID: 31295325; PMCID: PMC6622554.
   PubMed Web of Science ®Google Scholar
• Manix M, Kalakoti P, Henry M, et al. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus. 2015;39(5):E2.
   PubMed Web of Science ®Google Scholar
• Manuelidis L, Fritch W, Zaitsev I. Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet. 1998;352(9126):456.
   PubMed Web of Science ®Google Scholar
• Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology. 2004;62(5):714–718.
   PubMed Web of Science ®Google Scholar
• Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35(1):441–468.
   PubMed Web of Science ®Google Scholar